Bi Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bi Huang has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Suxin Luo
Department of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, China
29 shared publications Suxin Luo
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University
15 shared publications- Bryan Richard Sasmita
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
12 shared publications Linfeng Xie
12 shared publicationsYuanzhu Li
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University
12 shared publicationsJing Chen
10 shared publications
Latest Publications
- 16 October 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (11) , 251
Apolipoprotein A1 attenuates epirubicin-induced cardiotoxicity with GPX4-linked ferroptosis-defense modulation
Anthracycline-induced cardiotoxicity (AIC), in which ferroptosis-related cardiomyocyte injury has been implicated, remains a major challenge in oncology. This study investigates the therapeutic potential of an apolipoprotein A1 (ApoA1) mimetic peptide, L-4 F, in epirubicin-induced cardiotoxicity (EIC) in a rat model. Rats received epirubicin (2.5 mg/kg/week, i.p.) for six weeks to establish the EIC model, with or without concurrent ApoA1 mimetic treatment (L-4 F, 1 mg/kg/day). Cardiac function was assessed by echocardiography. Myocardial tissues underwent single-nucleus RNA sequencing (snRNA-seq), RegDiffusion-based gene regulatory network inference, Western blot, immunohistochemistry, and ELISA. Mechanistic studies used H9C2 cardiomyoblasts and CMEC-H9C2 Transwell co-culture systems under EPI exposure, with ApoA1 treatment, endothelial IL-33 knockdown, and Ferrostatin-1 (Fer-1) rescue. Glutathione peroxidase 4 (GPX4) expression, intracellular iron, lipid peroxidation, and cell viability were assessed. ApoA1 treatment alleviated diastolic dysfunction and weight loss and partially improved global longitudinal strain. snRNA-seq revealed substantial transcriptional remodeling in cardiomyocytes. RegDiffusion analysis identified coordinated reprogramming of transcription factor regulons, including Ppara, Fos, Egr1, and Klf4. ApoA1 treatment was associated with an anti-ferroptotic pattern of ferroptosis-related gene expression, with relatively higher Gpx4 and Slc7a11 expression and lower Tfrc expression, consistent with increased GPX4 protein levels. Intercellular communication analysis suggested enhanced IL-33/ST2-mediated endothelial-cardiomyocyte signaling following ApoA1 treatment. In vitro, ApoA1 restored GPX4 expression and reduced iron accumulation under EPI stress; these effects were potentiated in co-culture conditions and attenuated by endothelial IL-33 knockdown. In the rescue model, ApoA1 and Fer-1 partially restored viability and reduced MDA. ApoA1 alone did not significantly lower C11-BODIPY oxidation, whereas the combination gave the most consistent effect. ApoA1 attenuates EIC and is associated with modulation of GPX4-linked ferroptosis-related responses. This protective effect may involve endothelial-cardiomyocyte crosstalk, with endothelial IL-33 signaling acting as a partial contributor. These findings highlight a potential cardioprotective mechanism.
- 16 October 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (11) , 251
Apolipoprotein A1 attenuates epirubicin-induced cardiotoxicity with GPX4-linked ferroptosis-defense modulation
Anthracycline-induced cardiotoxicity (AIC), in which ferroptosis-related cardiomyocyte injury has been implicated, remains a major challenge in oncology. This study investigates the therapeutic potential of an apolipoprotein A1 (ApoA1) mimetic peptide, L-4 F, in epirubicin-induced cardiotoxicity (EIC) in a rat model. Rats received epirubicin (2.5 mg/kg/week, i.p.) for six weeks to establish the EIC model, with or without concurrent ApoA1 mimetic treatment (L-4 F, 1 mg/kg/day). Cardiac function was assessed by echocardiography. Myocardial tissues underwent single-nucleus RNA sequencing (snRNA-seq), RegDiffusion-based gene regulatory network inference, Western blot, immunohistochemistry, and ELISA. Mechanistic studies used H9C2 cardiomyoblasts and CMEC-H9C2 Transwell co-culture systems under EPI exposure, with ApoA1 treatment, endothelial IL-33 knockdown, and Ferrostatin-1 (Fer-1) rescue. Glutathione peroxidase 4 (GPX4) expression, intracellular iron, lipid peroxidation, and cell viability were assessed. ApoA1 treatment alleviated diastolic dysfunction and weight loss and partially improved global longitudinal strain. snRNA-seq revealed substantial transcriptional remodeling in cardiomyocytes. RegDiffusion analysis identified coordinated reprogramming of transcription factor regulons, including Ppara, Fos, Egr1, and Klf4. ApoA1 treatment was associated with an anti-ferroptotic pattern of ferroptosis-related gene expression, with relatively higher Gpx4 and Slc7a11 expression and lower Tfrc expression, consistent with increased GPX4 protein levels. Intercellular communication analysis suggested enhanced IL-33/ST2-mediated endothelial-cardiomyocyte signaling following ApoA1 treatment. In vitro, ApoA1 restored GPX4 expression and reduced iron accumulation under EPI stress; these effects were potentiated in co-culture conditions and attenuated by endothelial IL-33 knockdown. In the rescue model, ApoA1 and Fer-1 partially restored viability and reduced MDA. ApoA1 alone did not significantly lower C11-BODIPY oxidation, whereas the combination gave the most consistent effect. ApoA1 attenuates EIC and is associated with modulation of GPX4-linked ferroptosis-related responses. This protective effect may involve endothelial-cardiomyocyte crosstalk, with endothelial IL-33 signaling acting as a partial contributor. These findings highlight a potential cardioprotective mechanism.
- Open Access
- 8 September 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1879549
Case Report: Hereditary ATTR-CA presenting with recurrent severe abdominal cramps: a diagnostic challenge
Background: Hereditary transthyretin cardiac amyloidosis (ATTR-CA) is a rare autosomal dominant systemic disorder characterized by amyloid deposition in the peripheral nerves, myocardium, kidneys, and gastrointestinal tract. The clinical manifestations of ATTR-CA are nonspecific, resulting in high rates of misdiagnosis and underdiagnosis. Case presentation: We report the case of a 58-year-old woman who presented with recurrent severe abdominal pain and echocardiographic evidence of ventricular hypertrophy. Initial cardiac magnetic resonance imaging at an outside institution suggested left ventricular non-compaction (LVNC). Prior to receiving the correct diagnosis, she was incorrectly diagnosed with chronic cholecystitis, somatic symptom disorder, or LVNC at multiple institutions. A multidisciplinary team evaluation integrating cardiac imaging, technetium-99m phosphate scintigraphy, and genetic testing confirmed the diagnosis of ATTR-CA associated with the Ser23Asn (TTR c.128G>A p.Ser43Asn) variant. She was treated with tafamidis but died suddenly only two months after diagnosis. This case illustrates the multisystem involvement of ATTR-CA, in which atypical presentations frequently result in diagnostic delays. It represents a rarely reported instance of ATTR-CA presenting primarily with severe recurrent abdominal pain. Conclusion: In patients with ventricular hypertrophy, ATTR-CA may manifest with atypical symptoms such as severe, recurrent abdominal pain, which can result from autonomic neuropathy or gastrointestinal amyloid deposition. When the clinical diagnosis remains uncertain, multidisciplinary team consultation is essential to synthesize all available findings.
- 8 September 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1879549
Open AccessCase Report: Hereditary ATTR-CA presenting with recurrent severe abdominal cramps: a diagnostic challenge
Background: Hereditary transthyretin cardiac amyloidosis (ATTR-CA) is a rare autosomal dominant systemic disorder characterized by amyloid deposition in the peripheral nerves, myocardium, kidneys, and gastrointestinal tract. The clinical manifestations of ATTR-CA are nonspecific, resulting in high rates of misdiagnosis and underdiagnosis. Case presentation: We report the case of a 58-year-old woman who presented with recurrent severe abdominal pain and echocardiographic evidence of ventricular hypertrophy. Initial cardiac magnetic resonance imaging at an outside institution suggested left ventricular non-compaction (LVNC). Prior to receiving the correct diagnosis, she was incorrectly diagnosed with chronic cholecystitis, somatic symptom disorder, or LVNC at multiple institutions. A multidisciplinary team evaluation integrating cardiac imaging, technetium-99m phosphate scintigraphy, and genetic testing confirmed the diagnosis of ATTR-CA associated with the Ser23Asn (TTR c.128G>A p.Ser43Asn) variant. She was treated with tafamidis but died suddenly only two months after diagnosis. This case illustrates the multisystem involvement of ATTR-CA, in which atypical presentations frequently result in diagnostic delays. It represents a rarely reported instance of ATTR-CA presenting primarily with severe recurrent abdominal pain. Conclusion: In patients with ventricular hypertrophy, ATTR-CA may manifest with atypical symptoms such as severe, recurrent abdominal pain, which can result from autonomic neuropathy or gastrointestinal amyloid deposition. When the clinical diagnosis remains uncertain, multidisciplinary team consultation is essential to synthesize all available findings.
- Open Access
- 20 August 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (11) , 2588-2604
Epidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia
- 20 August 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (11) , 2588-2604
Open AccessEpidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia
- Open Access
- 15 August 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 226
Differential myocardial responses to indobufen and aspirin across clinical and experimental models of myocardial infarction
- 15 August 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 226
Open AccessDifferential myocardial responses to indobufen and aspirin across clinical and experimental models of myocardial infarction
- Open Access
- 11 August 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1901732
Fabry cardiomyopathy presenting as hypertrophic phenotype with left ventricular outflow tract obstruction: a case series
Background: Fabry disease is a cardiomyopathy with multisystemic manifestations that is easily to be misdiagnosed as another type of cardiomyopathy. Fabry cardiomyopathy may present with left ventricular outflow tract obstruction (LVOTO), mimicking obstructive hypertrophic cardiomyopathy (oHCM). We present three cases of genetically confirmed Fabry disease that were initially misdiagnosed as oHCM, highlighting the importance of early recognition and tailored management. Methods: We performed Fabry disease screening on patients diagnosed with oHCM and ultimately identified three individuals who have received oHCM-specific treatments including mavacamten and alcohol septal ablation. Results: Three patients (2 females, 1 male; aged 48–66 years) who were initially diagnosed with and managed for oHCM based on septal hypertrophy and elevated left ventricular outflow tract gradients (LVOTG), was found to have GLA gene mutations. Enzyme replacement therapy with agalsidase alfa in two patients was associated with stabilization or improvement in wall thickness and LVOTO. Conclusion: Fabry cardiomyopathy can present with a hypertrophic phenotype and significant LVOTO, and is often misdiagnosed as oHCM. This further underscores the importance of genetic testing in the etiological diagnosis of hypertrophic cardiomyopathies. Enzyme replacement therapy may ameliorate obstruction, while mavacamten and septal reduction therapies require caution without definitive genotype-phenotype correlation.
- 11 August 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1901732
Open AccessFabry cardiomyopathy presenting as hypertrophic phenotype with left ventricular outflow tract obstruction: a case series
Background: Fabry disease is a cardiomyopathy with multisystemic manifestations that is easily to be misdiagnosed as another type of cardiomyopathy. Fabry cardiomyopathy may present with left ventricular outflow tract obstruction (LVOTO), mimicking obstructive hypertrophic cardiomyopathy (oHCM). We present three cases of genetically confirmed Fabry disease that were initially misdiagnosed as oHCM, highlighting the importance of early recognition and tailored management. Methods: We performed Fabry disease screening on patients diagnosed with oHCM and ultimately identified three individuals who have received oHCM-specific treatments including mavacamten and alcohol septal ablation. Results: Three patients (2 females, 1 male; aged 48–66 years) who were initially diagnosed with and managed for oHCM based on septal hypertrophy and elevated left ventricular outflow tract gradients (LVOTG), was found to have GLA gene mutations. Enzyme replacement therapy with agalsidase alfa in two patients was associated with stabilization or improvement in wall thickness and LVOTO. Conclusion: Fabry cardiomyopathy can present with a hypertrophic phenotype and significant LVOTO, and is often misdiagnosed as oHCM. This further underscores the importance of genetic testing in the etiological diagnosis of hypertrophic cardiomyopathies. Enzyme replacement therapy may ameliorate obstruction, while mavacamten and septal reduction therapies require caution without definitive genotype-phenotype correlation.
- 25 June 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (8) , 1717-1718
Response to comments on “Predictive value of LDL/HDL cholesterol ratio for new-onset stroke in individuals with cardiovascular-kidney-metabolic syndrome stages 0 to 3: Evidence from the China Health and Retirement Longitudinal Study”
- 25 June 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (8) , 1717-1718
Response to comments on “Predictive value of LDL/HDL cholesterol ratio for new-onset stroke in individuals with cardiovascular-kidney-metabolic syndrome stages 0 to 3: Evidence from the China Health and Retirement Longitudinal Study”
- Top Cited Papers
- 9 April 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113258
The combined estimated glucose disposal rate and frailty index predicts cardiovascular events and mortality: A prospective cohort study from CHARLS
- 9 April 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113258
Top Cited PapersThe combined estimated glucose disposal rate and frailty index predicts cardiovascular events and mortality: A prospective cohort study from CHARLS
- Open Access
- 26 March 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (24) , 107640
Catecholamine-Induced Cardiomyopathy Initially Misdiagnosed as Myocarditis in a Patient With Pheochromocytoma
- 26 March 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (24) , 107640
Open AccessCatecholamine-Induced Cardiomyopathy Initially Misdiagnosed as Myocarditis in a Patient With Pheochromocytoma
- Open Access
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1762912
Total body water to lean body mass ratio predicts mortality in patients with chronic heart failure: a prospective, observational study
Background: Malnutrition and sodium water retention are some of the most common complications of chronic heart failure (CHF). To date, several parameters or risk stratification tools have been established to predict one’s volume or nutritional status. Unfortunately, there is no biomarker that may reflect both conditions, thus, in this study, we established a novel biomarker known as total body water (TBW) to lean body mass ratio (LBM) ratio (TLR). Accordingly, we also assessed the prognostic value of TLR in CHF patients. Methods: A total of 401 consecutive patients with CHF from August 2019 to October 2021 were prospectively enrolled. TBW and LBM were obtained by InBody S10. The primary endpoint was long-term all-cause and cardiovascular mortality. The cut-off and prognostic value of TLR was determined by receiver operating characteristic curves and Cox regression analysis. Patients were then divided into two groups according to the cut-off value of TLR. Results: During a median follow-up of 1,200 days, the high-TLR group (TLR ≥ 0.783) was presented with a higher all-cause mortality (41.27% vs. 18.40%, p < 0.001) and cardiovascular mortality (28.57% vs. 13.68%, p < 0.001) compared to the low-TLR group (TLR < 0.783). Furthermore, patients in the high-TLR group tended to be older, presented with atrial fibrillation, had higher NYHA class, had a history of chronic kidney disease, had a higher level of N-terminal prohormone of brain natriuretic peptide, worse nutritional status, and a lower level of albumin (all p < 0.05). The Kaplan–Meier curves of the two group patients revealed that the cumulative all-cause and cardiovascular mortality were lower in patients with lower TLR (all log-rank p < 0.001). In the multivariate Cox proportional hazard analysis, TLR ≥ 0.783 was an independent predictor for both all-cause mortality (HR = 2.108, 95%CI 1.400, 3.173, p < 0.001) and cardiovascular mortality (HR = 2.044, 95%CI 1.264, 3.305, p = 0.004). Conclusion: The TLR may serve as a novel composite biomarker that reflects both volume and nutritional status in CHF patients and is associated with long-term prognosis. Its prognostic performance appears comparable to several established biomarkers, though further validation is warranted.
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1762912
Open AccessTotal body water to lean body mass ratio predicts mortality in patients with chronic heart failure: a prospective, observational study
Background: Malnutrition and sodium water retention are some of the most common complications of chronic heart failure (CHF). To date, several parameters or risk stratification tools have been established to predict one’s volume or nutritional status. Unfortunately, there is no biomarker that may reflect both conditions, thus, in this study, we established a novel biomarker known as total body water (TBW) to lean body mass ratio (LBM) ratio (TLR). Accordingly, we also assessed the prognostic value of TLR in CHF patients. Methods: A total of 401 consecutive patients with CHF from August 2019 to October 2021 were prospectively enrolled. TBW and LBM were obtained by InBody S10. The primary endpoint was long-term all-cause and cardiovascular mortality. The cut-off and prognostic value of TLR was determined by receiver operating characteristic curves and Cox regression analysis. Patients were then divided into two groups according to the cut-off value of TLR. Results: During a median follow-up of 1,200 days, the high-TLR group (TLR ≥ 0.783) was presented with a higher all-cause mortality (41.27% vs. 18.40%, p < 0.001) and cardiovascular mortality (28.57% vs. 13.68%, p < 0.001) compared to the low-TLR group (TLR < 0.783). Furthermore, patients in the high-TLR group tended to be older, presented with atrial fibrillation, had higher NYHA class, had a history of chronic kidney disease, had a higher level of N-terminal prohormone of brain natriuretic peptide, worse nutritional status, and a lower level of albumin (all p < 0.05). The Kaplan–Meier curves of the two group patients revealed that the cumulative all-cause and cardiovascular mortality were lower in patients with lower TLR (all log-rank p < 0.001). In the multivariate Cox proportional hazard analysis, TLR ≥ 0.783 was an independent predictor for both all-cause mortality (HR = 2.108, 95%CI 1.400, 3.173, p < 0.001) and cardiovascular mortality (HR = 2.044, 95%CI 1.264, 3.305, p = 0.004). Conclusion: The TLR may serve as a novel composite biomarker that reflects both volume and nutritional status in CHF patients and is associated with long-term prognosis. Its prognostic performance appears comparable to several established biomarkers, though further validation is warranted.